Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Palivizumab treatment of infants at high risk of Respiratory Syncytial Virus (RSV) infections: outcomes of specialty pharmacy services

  • At: 2007 FIP Congress in Beijing (China)
  • Type: Presentations + Posters
  • By: ADDO-ATUAH, Joyce (University of Tennessee, Memphis, United States of America)
  • Co-author(s): Gourley, Dick (University of Tennessee, Memphis, United States of America)
    Faris, Richard (Nova Factor Incorporated, Memphis, United States of America)
    McKinnon, Barbara (Nova Factor Incorporated, Memphis, United States of America)
    Bush, Andrew J. (University of Tennessee, Memphis, United States of America)
    Gourley, Greta (University of Tennessee, Memphis, United States of America)
  • Abstract:

    Background: The unique characteristics of specialty biopharmaceutical products require special and often product-specific patient services to optimize their therapeutic benefits so as to compensate for their relatively high costs. Objective: To describe the product-specific service model developed by a specialty pharmacy provider for palivizumab

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses